Craft

AC Immune

Stock Price

$3.5

2024-07-08

Market Capitalization

$344.2 M

2024-07-08

Revenue

CHF14.8 M

FY, 2023

AC Immune Summary

Company Summary

Overview
AC Immune is a biopharmaceutical company developing therapeutics against Alzheimer´s disease and other conformational diseases. Its technology platforms allow to discover, design, and develop antibodies, small molecules, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
Type
Public
Status
Active
Founded
2003
HQ
Lausanne, CH | view all locations
Website
https://www.acimmune.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Andrea Pfeifer

    Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director

  • Marie Kosco-Vilbois

    Marie Kosco-Vilbois, Chief Scientific Officer

  • Johannes Streffer

    Johannes Streffer, Chief Medical Officer

  • Christopher Roberts

    Christopher Roberts, Interim Chief Financial Officer Vice President, Finance

Operating MetricsView all

Partnered Products

5

Q3, 2022

Products in Development

16

Q3, 2022

LocationsView all

1 location detected

  • Lausanne, VD HQ

    Switzerland

    EPFL Innovation Park-Building B

AC Immune Financials

Summary Financials

Revenue (FY, 2023)
CHF14.8M
Gross profit (FY, 2023)
CHF16.3M
Net income (FY, 2023)
(CHF54.2M)
Cash (FY, 2023)
CHF78.5M
EBIT (FY, 2023)
(CHF53.6M)
Enterprise value
$269.2M

Footer menu